Acyl glucuronidation of fluoroquinolone antibiotics by the UDP-glucuronosyltransferase 1A subfamily in human liver microsomes

Drug Metabolism and Disposition

Volumn 33, Issue 6, 2005, Pages 803-811

  Tachibana, Masaya ^a,b   Tanaka, Makoto ^b   Masubuchi, Yasuhiro ^a   Horie, Toshiharu ^a  

^a CHIBA UNIVERSITY   (Japan)

^b DAIICHI SANKYO CO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; COMPLEMENTARY DNA; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A3; GLUCURONOSYLTRANSFERASE 1A7; GLUCURONOSYLTRANSFERASE 1A9; GREPAFLOXACIN; LEVOFLOXACIN; MEFENAMIC ACID; MOXIFLOXACIN; PROPOFOL; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RECOMBINANT ENZYME; SITAFLOXACIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CATALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG CLEARANCE; DRUG INHIBITION; DRUG MECHANISM; DRUG STRUCTURE; ENZYME KINETICS; GLUCURONIDATION; HUMAN; HUMAN CELL; IC 50; LIVER MICROSOME; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; BILIRUBIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUOROQUINOLONES; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; MALE; MICROSOMES, LIVER; MULTIGENE FAMILY; RATS; RATS, SPRAGUE-DAWLEY;

EID: 18844452950     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.104.003178     Document Type: Article

References (38)

1. Akiyama H, Koike M, Kyuushiki K, Suzuki T, Kusumoto N, Morita S, and Odomi M (1995) Pharmacokinetics of grepafloxacin (IV) - metabolism after oral administration of grepafloxacin in rats, monkeys and humans. Chemotherapy 43 (Suppl 1):131-149.
2. Andersson MI and MacGowan AP (2003) Development of the quinolones. J Antimicrob Chemother 51 (Suppl S1):1-11.
3. Appelbaum PC and Hunter PA (2000) The fluoroquinolone antibacterials: past, present and future perspectives. Int J Antimicrob Agents 16:5-15.
4. Bailey MJ and Dickinson RG (2003) Acyl glucuronide reactivity in perspective: biological consequences. Chem-Biol Interact 145:117-137.
5. Ball P (2003) Adverse drug reactions: implications for the development of fluoroquinolones. J Antimicrob Chemother 51 (Suppl 1):21-27.
6. Bosma PJ, Seppen J, Goldhoorn B, Bakker C, Oude Elferink RP, Chowdhury JR, Chowdhury NR, and Jansen PL (1994) Bilirubin UDP-glucuronosyltransferase 1 is the only relevant bilirubin glucuronidating isoform in man. J Biol Chem 269:17960-17964.
7. Burchell B, Brierley CH, and Rance D (1995) Specificity of human UDP-glucuronosyltransferases and xenobiotic glucuronidation. Life Sci 57:1819-1831.
8. Coffman BL, Rios GR, King CD, and Tephly TR (1997) Human UGT2B7 catalyzes morphine glucuronidation. Drug Metab Dispos 25:1-4.
9. Dalvie DK, Khosla N, and Vincent J (1997) Excretion and metabolism of trovafloxacin in humans. Drug Metab Dispos 25:423-427.
10. Dudley MN (2003) Pharmacokinetics of fluoroquinolones, in Quinolone Antimicrobial Agents, 3rd ed (Hooper DC and Rubinstein E eds) pp 115-132, ASM Press, Washington, DC.
11. Emmerson AM and Jones AM (2003) The quinolones: decades of development and use. J Antimicrob Chemother 51 (Suppl S1):13-20.
12. Fish DN and Chow AT (1997) The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet 32:101-119.
13. Green MD and Tephly TR (1995) Glucuronidation of amines and hydroxylated xenobiotics and endobiotics catalyzed by expressed human UGT1.4 protein. Drug Metab Dispos 24:356-363.
14. Hooper DC (1998) Clinical applications of quinolones. Biochim Biophys Acta 1400:45-61.
15. Houston JB, Kenworthy KE, and Galetin A (2003) Typical and atypical enzyme kinetics, in Drug Metabolising Enzymes (Lee JS, Obach RS, and Fisher MB eds) pp 211-254, Marcell Dekker Inc., New York.
16. Jin C, Miners JO, Lillywhite KJ, and Mackenzie PI (1993) Complementary deoxyribonucleic acid cloning and expression of a human liver uridine diphosphate-glucuronosyltransferase glucuronidating carboxylic acid-containing drugs. J Pharmacol Exp Ther 264:475-479.
17. King C, Tang W, Ngui J, Tephly T, and Braun M (2001) Characterization of rat and human UDP-glucuronosyltransferases responsible for the in vitro glucuronidation of diclofenac. Toxicol Sci 61:49-53.
18. Lubasch A, Keller I, Borner K, Koeppe P, and Lode H (2000) Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin and moxifloxacin after single oral administration in healthy volunteers. Antimicrob Agents Chemother 44:2600-2603.
19. Mackenzie PI, Owens IS, Burchell B, Bock KW, Bairoch A, Belanger A, Fournel-Gigleux S, Green M, Hum DW, Iyanagi T, et al. (1997) The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. Pharmacogenetics 7:255-269.
20. McGurk KA, Remmel RP, Hosagrahara VP, Tosh D, and Burchell B (1996) Reactivity of mefenamic acid 1-O-acyl glucuronide with proteins in vitro and ex vivo. Drug Metab Dispos 24:842-849.
21. Miners JO, Smith PA, Sorich MJ, McKinnon RA, and Mackenzie PI (2004) Predicting human drug glucuronidation parameters: application of in vitro and in silico modeling approaches. Annu Rev Phannacol Toxicol 44:1-25.
22. Mojarrabi B, Butler R, and Mackenzie PI (1996) cDNA cloning and characterization of the human UDP glucuronosyltransferase, UGT1A3. Biochem Biophys Res Commun 225:785-790.
23. Montay G (1996) Pharmacokinetics of sparfloxacin in healthy volunteers and patients: a review. J Antimicrob Chemother 37 (Suppl A):27-39.
24. O'Grady J, Briggs A, Atarashi S, Kobayashi H, Smith RL, Ward J, Ward C, and Milatovic D (2001) Pharmacokinetics and absolute bioavailability of sitafloxacin, a new fluoroquinolone antibiotic, in healthy male and female Caucasian subjects. Xenobiotica 31:811-822.
25. Owens IS and Ritter JK (1995) Gene structure at the human UGT1 locus creates diversity in isozyme structure, substrate specificity and regulation. Prog Nucleic Acid Res Mol Biol 51:305-338.
26. Radominska-Pandya A, Czernik PJ, Little JM, Battaglia E, and Mackenzie PI (1999) Structural and functional studies of UDP-glucuronosyltransferases. Drug Metab Rev 31:817-899.
27. Sakaguchi K, Green M, Stock N, Reger TS, Zunic J, and King C (2004) Glucuronidation of carboxylic acid containing compounds by UDP- giucuronosyltransferase isoforms. Arch Biochem Biophys 424:219-225.
28. Senafi SB, Clarke DJ, and Burchell B (1994) Investigation of the substrate specificity of a cloned expressed human bilirubin UDP- glucuronosyltransferase: UDP-sugar specificity and involvement in steroid and xenobiotic glucuronidation. Biochem J 303:233-240.
29. Shipkova M, Armstrong VW, Oellerich M, and Wieland E (2003) Acyl glucuronide drug metabolites: toxicological and analytical implications. Ther Drug Monit 25:1-16.
30. Spahn-Langguth H and Benet LZ (1992) Acyl glucuronides revisited: is the glucuronidation process a toxification as well as a detoxification mechanism? Drug Metab Rev 24:5-47.
31. Stass H and Kubitza DJ (1999) Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. Antimicrob Chemother 43 (Suppl B):83-90.
32. Stone AN, Mackenzie PI, Galetin A, Houston JB, and Miners JO (2003) Isoform selectivity and kinetics of morphine 3- and 6-glucuronidation by human UDP-glucuronosyltransferases: evidence for atypical glucuronidation kinetics by UGT2B7. Drug Metab Dispos 31:1086-1089.
33. Strassburg CP, Oldhafer K, Manns MP, and Tukey RH (1997) Differential expression of the UGT1A locus in human liver, biliary and gastric tissue: identification of UGT1A7 and UGT1A10 transcripts in extrahepatic tissue. Mol Pharmacol 52:212-220.
34. Tachibana M, Tanaka M, Mitsugi K, Jin Y, Takaichi M, and Okazaki O (2004) Pharmacokinetics, tissue distribution, and disposition of sitafloxacin, a new fluoroquinolone antibiotic, in rats, dogs and monkeys. Arzneim-Forsch/Drug Res 54:898-905.
35. A receptor antagonist in human liver microsomes. Drug Metab Dispos 31:37-45.
36. Tukey RH and Strassburg CP (2000) Human UDP-glucuronosyltransferases: metabolism, expression and disease. Annu Rev Pharmacol Toxicol 40:581-616.
37. Williams JA, Ring BJ, Cantrell VE, Campanale K, Jones DR, Hall SD, and Wrighton SA (2002) Differential modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1)-catalyzed estradiol-3-glucuronidation by the addition of UGT1A1 substrates and other compounds to human liver microsomes. Drug Metab Dispos 30:1266-1273.
38. Wynalda MA, Wynalda KM, Amore BM, Fagerness PE, and Wienkers LC (2003) Characterization of bropirimine O-glucuronidation in human liver microsomes. Xenobiotica 33:999-1011.